Status:
COMPLETED
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients
Lead Sponsor:
Shaare Zedek Medical Center
Conditions:
Cancer
Thrombosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to determine the Pharmacokinetics of Low Molecular Weight Heparin (LMWH) in Cancer patients, and compare it to the Pharmacokinetics of LMWH in Patients without cancer. We a...
Detailed Description
Scientific background. The increased risk for venous thromboembolism (VTE) in cancer has long been recognized (1). Since first described by Trousseau in 1865, many aspects of this complex relationship...
Eligibility Criteria
Inclusion
- Treatment with therapeutic dose of low molecular weight heparin
- Serum creatinine level \< 1.5 mg/dl.
Exclusion
- major surgery during the last month before investigation
- evidence of major infectious disease
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00716898
Start Date
February 1 2009
End Date
June 1 2011
Last Update
April 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaare Zedek Medicla Center
Jerusalm, Israel, Israel, 91031